Key facts
- This page summarizes Braden M. Leonard's Form 4 filing for Tectonic Therapeutic, Inc. (TECX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 25 Jun 2024, 13:42.
Braden M. Leonard - 20 Jun 2024 Form 4 Insider Report for Tectonic Therapeutic, Inc. (TECX)
- Reporting relationship
- Former 10% owner of AVROBIO
- Issuer ticker
- TECX
- Reported as of
- 20 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jun 2024, 13:42:11 UTC
- Prior SEC filing
- 18 Jun 2024
- Next SEC filing
- 01 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- Braden Michael Leonard
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Braden M. Leonard filed Form 4 for Tectonic Therapeutic, Inc. (TECX) on 25 Jun 2024.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TECX
transaction
Common Stock
Other
- Transaction value
- Shares
- +400,355
- Change %
- Price
- Shares after
- 400,355
- Date
- 20 Jun 2024
- Ownership
- Holding of BML Investment Partners, L.P,
- Footnotes
- F1, F2
TECX
transaction
Common Stock
Other
- Transaction value
- Shares
- +33,333
- Change %
- Price
- Shares after
- 33,333
- Date
- 20 Jun 2024
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Received in exchange for 4,768,262 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.
Footnote F2
BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Footnote F3
Received in exchange for 400,000 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.